Proportion of products that undergo a full or simplified Life Cycle Assessment (LCA), calculated using revenues as the denominator
Unit
i
The unit(s) of measurement applicable to the metric.
: Percentage (%)
Indicator
i
Indicators were developed by WBCSD. Learn more on the Methodology page.
: Resource consumption
Metric type
i
The category of nature-related metrics. Learn more on the Methodology page.
: Pressure
Framework alignment notes
i
The details of a metric’s alignment to each framework, including where the same or similar metric can be found within the listed framework.
ESRS This metric is aligned with the requirements of the framework.
TNFD BP.A23.0
Refer to EFPIA's Clear Steps Toward a Greener Future - Pharmaceutical Sector’s Environmental Sustainability Statement (10.06.24) for alignment to metric
GBF Target 7, Target 16
Target example
i
An example target and the target source are presented to illustrate how a target could be set for this metric. Learn more on the Methodology page.
[Company name] will assess [target amount]% of products—accounting for [target amount]%% of total revenue—undergo a full or simplified Life Cycle Assessment (LCA) by [target year], compared to a [baseline year] baseline, to better understand and manage nature-related dependencies and impacts
Target source: WBCSD target template
Sector
i
Each metric applies to one sector.
Pharmaceutical
Value chain stage
i
Each metric applies to one or more stages of the value chain aligned with the associated actions.
Raw MaterialsManufacturingEnd of Life
Metric assessment
i
The relevance and feasibility scores were determined by WBCSD member companies. Learn more on the Methodology page.
Relevance:High
Feasibility:Medium
Related actions
i
The other actions that the metric is mapped to.
Use recycled, renewable, or biodegradable materials to reduce reliance on virgin and fossil-based resources
Reduce water use and wastage, particularly in water-stressed areas
Reduce GHG emissions in products
Reduce operational waste through improved material efficiency and reuse
Reduce solid waste generated from the disposal of used pharmaceutical products through public education and information campaigns encouraging correct packaging and device disposal
Reduce the release of non-GHG air pollutants from waste air through interventions including, but not limited to, enhanced air filtration systems or production step efficiency measures
Reduce upstream water use by engaging with suppliers and encouraging the adoption of more water-efficient processes, particularly in water-stressed areas
Reduce water and soil pollution risk from APIs, especially antibiotics, harmful chemicals and other relevant substances from manufacturing sites
Minimize waste from single-use packaging by redesigning products and systems to prioritize circularity
Design processes and products to minimize waste and maximize circularity
Develop and implement sourcing guidelines that prioritize sustainable commodities and suppliers committed to sustainable practices